<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740155</url>
  </required_header>
  <id_info>
    <org_study_id>CYD11</org_study_id>
    <nct_id>NCT00740155</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults</brief_title>
  <official_title>Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is part of an ongoing effort to develop a satisfactory dengue vaccine:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To describe the safety after each vaccination with bivalent and tetravalent formulations of&#xD;
      dengue vaccine candidates.&#xD;
&#xD;
      To describe the immune response after each vaccination of dengue vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to five groups to receive assigned vaccines and followed up for&#xD;
      12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: To provide information concerning the safety of ChimeriVax™ Dengue Vaccine</measure>
    <time_frame>12 months post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Dengue Virus</condition>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <condition>Dengue Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetravalent CYD-1,2,3,4 Dengue (Vero)</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)</intervention_name>
    <description>0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)</description>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>JE-VAX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Healthy as determined by medical history, clinical examination, and biological safety&#xD;
             parameters&#xD;
&#xD;
          -  Aged 18 to 45 years on the day of inclusion.&#xD;
&#xD;
          -  Informed consent form signed.&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
          -  For a woman of child-bearing potential, use of an effective method of contraception or&#xD;
             abstinence for at least 4 weeks prior to the first vaccination and at least 4 weeks&#xD;
             after the last vaccination.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  History of thymic diseases or thymectomy.&#xD;
&#xD;
          -  For a woman of child-bearing potential, known or suspected pregnancy or positive&#xD;
             pregnancy test&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Current abuse of alcohol or drug addiction that may interfere with the subject's&#xD;
             ability to comply with trial procedures.&#xD;
&#xD;
          -  Subject deprived of freedom by an administrative or court order, or in an emergency&#xD;
             setting, or hospitalized without his/her consent.&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV), Hepatitis B (HBs Ag) or Hepatitis C (HC)&#xD;
             seropositivity in blood sample taken at screening.&#xD;
&#xD;
          -  Laboratory abnormalities considered clinically significant upon the Investigator's&#xD;
             judgment or above the intensity thresholds (defined in the protocol) in blood sample&#xD;
             taken at screening.&#xD;
&#xD;
          -  Participation in another clinical trial in the 4 weeks preceding the first trial&#xD;
             vaccination.&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period.&#xD;
&#xD;
          -  Previous residence in or travel of more than 2 weeks to areas with high dengue&#xD;
             infection endemicity.&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or a vaccine containing the same&#xD;
             substances (i.e. egg, egg products, proteins of rodent or neural origin, gelatin, and&#xD;
             thimerosal.&#xD;
&#xD;
          -  History of urticaria after hymenoptera envenomation.&#xD;
&#xD;
          -  History of flavivirus infection as reported by the subject.&#xD;
&#xD;
          -  Previous vaccination against flavivirus diseases (including Japanese encephalitis,&#xD;
             tick-borne encephalitis, and yellow fever).&#xD;
&#xD;
          -  Planned travel during the present trial period to areas with high dengue infection&#xD;
             endemicity.&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer&#xD;
             chemotherapy or radiation therapy within the preceding 6 months, or long-term (at&#xD;
             least 2 weeks within the previous 3 months) systemic corticosteroid therapy (at a dose&#xD;
             of a t least 10 mg).&#xD;
&#xD;
          -  Chronic illness at a stage that could interfere with trial conduct or completion.&#xD;
&#xD;
          -  Blood or blood-derived products received in the past 3 months.&#xD;
&#xD;
          -  Any vaccination in the 4 weeks preceding the first trial vaccination.&#xD;
&#xD;
          -  Vaccination planned in the 4 weeks following any trial vaccination.&#xD;
&#xD;
          -  Flavivirus vaccination planned during the present trial period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tlalpan</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valle de Chalco</city>
        <zip>56613</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.</citation>
    <PMID>25483647</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>March 2, 2015</last_update_submitted>
  <last_update_submitted_qc>March 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue virus</keyword>
  <keyword>Dengue fever</keyword>
  <keyword>Dengue hemorrhagic fever</keyword>
  <keyword>Dengue diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

